Insulet Company Insiders
PODD Stock | USD 262.00 4.58 1.72% |
Insulet's insiders are aggressively selling. The analysis of insiders' sentiment of trading Insulet stock suggests that all insiders are panicking at this time. Insulet employs about 3 K people. The company is managed by 17 executives with a total tenure of roughly 46 years, averaging almost 2.0 years of service per executive, having 176.47 employees per reported executive.
James Hollingshead CEO CEO President |
Eric Benjamin President Senior Vice President R&D, New Product Development and Commercialization |
Insulet's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-06-14 | Mark N Field | Disposed 1500 @ 199.96 | View | ||
2024-06-10 | Timothy J Scannell | Disposed 7000 @ 190.51 | View | ||
2024-05-28 | Timothy J Scannell | Disposed 3300 @ 180.9 | View | ||
2024-04-04 | Tina Smith | Disposed @ 163.25 | |||
2024-02-28 | Shacey Petrovic | Disposed 11609 @ 162.92 | View |
Monitoring Insulet's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Insulet |
Insulet's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Insulet's future performance. Based on our forecasts, it is anticipated that Insulet will maintain a workforce of about 3000 employees by December 2024.Insulet's latest congressional trading
Congressional trading in companies like Insulet, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Insulet by those in governmental positions are based on the same information available to the general public.
2024-04-19 | Senator Tina Smith | Acquired $50K to $100K | Verify | ||
2024-01-26 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
2024-01-25 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
2018-09-19 | Senator Tina Smith | Acquired $15K to $50K | Verify | ||
2018-06-11 | Senator Tina Smith | Acquired $100K to $250K | Verify | ||
2018-03-06 | Senator Tina Smith | Acquired $100K to $250K | Verify |
Insulet Management Team Effectiveness
The company has return on total asset (ROA) of 0.0757 % which means that it generated a profit of $0.0757 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4879 %, meaning that it created $0.4879 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.09. The current year's Return On Capital Employed is expected to grow to 0.11. At present, Insulet's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.1 B, whereas Intangibles To Total Assets are forecasted to decline to 0.06.The current year's Net Income Applicable To Common Shares is expected to grow to about 5.6 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 44.7 M.
Insulet Workforce Comparison
Insulet is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 240,319. Insulet claims roughly 3,000 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of 0.21 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.16 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.16. Insulet Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insulet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insulet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Insulet insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 0.25 | 2 | 8 | 7,728 | 26,559 |
2024-06-01 | 1.0769 | 14 | 13 | 43,364 | 37,515 |
2024-03-01 | 1.0435 | 24 | 23 | 124,841 | 28,401 |
2023-12-01 | 0.2857 | 2 | 7 | 20,000 | 66,202 |
2023-09-01 | 0.4444 | 4 | 9 | 15,010 | 20,346 |
2023-06-01 | 1.5 | 9 | 6 | 10,044 | 21,160 |
2023-03-01 | 0.5424 | 32 | 59 | 159,898 | 157,561 |
2022-12-01 | 0.4615 | 6 | 13 | 48,778 | 95,456 |
2022-09-01 | 0.4 | 2 | 5 | 15,000 | 40,830 |
2022-06-01 | 1.2857 | 9 | 7 | 43,561 | 25,316 |
2022-03-01 | 0.9167 | 33 | 36 | 200,108 | 117,308 |
2021-12-01 | 0.4375 | 7 | 16 | 29,333 | 57,661 |
2021-09-01 | 0.3333 | 3 | 9 | 36,596 | 100,232 |
2021-06-01 | 0.9231 | 12 | 13 | 53,191 | 82,127 |
2021-03-01 | 0.8571 | 24 | 28 | 126,984 | 66,373 |
2020-12-01 | 0.6154 | 8 | 13 | 48,710 | 92,937 |
2020-09-01 | 0.25 | 2 | 8 | 8,392 | 129,944 |
2020-06-01 | 1.4286 | 10 | 7 | 12,921 | 9,098 |
2020-03-01 | 0.9565 | 22 | 23 | 141,163 | 85,580 |
2019-12-01 | 0.5 | 6 | 12 | 23,606 | 40,390 |
2019-09-01 | 0.3333 | 1 | 3 | 2,033 | 4,802 |
2019-06-01 | 1.1053 | 21 | 19 | 78,797 | 97,840 |
2019-03-01 | 0.5294 | 27 | 51 | 190,536 | 207,396 |
2018-12-01 | 0.375 | 3 | 8 | 12,947 | 23,825 |
2018-06-01 | 0.6364 | 14 | 22 | 42,738 | 85,028 |
2018-03-01 | 0.64 | 32 | 50 | 443,529 | 147,848 |
2017-12-01 | 1.0 | 1 | 1 | 2,500 | 1,967 |
2017-09-01 | 2.0 | 6 | 3 | 67,123 | 2,434 |
2017-06-01 | 6.3333 | 19 | 3 | 77,707 | 2,595 |
2017-03-01 | 1.3 | 26 | 20 | 335,781 | 174,818 |
2016-12-01 | 4.0 | 4 | 1 | 52,775 | 3,075 |
2016-06-01 | 2.5714 | 18 | 7 | 112,946 | 17,907 |
2016-03-01 | 2.3636 | 26 | 11 | 639,000 | 81,801 |
2015-09-01 | 1.0 | 3 | 3 | 14,081 | 29,581 |
2015-06-01 | 2.0909 | 23 | 11 | 211,450 | 40,675 |
2015-03-01 | 1.1875 | 19 | 16 | 1,005,711 | 52,117 |
2014-12-01 | 0.625 | 10 | 16 | 1,075,848 | 71,500 |
2014-09-01 | 0.4211 | 8 | 19 | 73,751 | 173,500 |
2014-06-01 | 1.0556 | 19 | 18 | 139,750 | 216,108 |
2014-03-01 | 0.8649 | 32 | 37 | 530,217 | 494,410 |
2013-12-01 | 0.4375 | 14 | 32 | 196,811 | 440,978 |
2013-09-01 | 0.4 | 4 | 10 | 90,000 | 194,000 |
2013-06-01 | 1.1429 | 24 | 21 | 179,647 | 270,323 |
2013-03-01 | 1.5 | 12 | 8 | 274,200 | 125,877 |
2012-12-01 | 0.4615 | 6 | 13 | 100,836 | 165,155 |
2012-09-01 | 0.5909 | 13 | 22 | 153,000 | 206,000 |
2012-06-01 | 1.5417 | 37 | 24 | 661,298 | 316,416 |
2012-03-01 | 0.325 | 13 | 40 | 111,339 | 869,947 |
2011-12-01 | 0.5 | 8 | 16 | 69,500 | 103,299 |
2011-09-01 | 0.6154 | 8 | 13 | 63,200 | 121,900 |
2011-06-01 | 1.1 | 22 | 20 | 176,196 | 270,392 |
2011-03-01 | 0.8788 | 29 | 33 | 752,789 | 409,403 |
2010-12-01 | 0.5 | 1 | 2 | 1,500 | 3,000 |
2010-09-01 | 0.5 | 5 | 10 | 12,000 | 24,000 |
2010-06-01 | 1.0 | 14 | 14 | 37,500 | 27,000 |
2010-03-01 | 0.7273 | 16 | 22 | 158,917 | 185,417 |
2009-12-01 | 0.3846 | 5 | 13 | 10,500 | 38,080 |
2009-09-01 | 1.3333 | 4 | 3 | 37,480 | 12,246 |
2009-06-01 | 1.0 | 3 | 3 | 1,130 | 1,130 |
2009-03-01 | 3.25 | 13 | 4 | 505,000 | 25,000 |
2008-12-01 | 3.0 | 18 | 6 | 43,151 | 15,733 |
2008-09-01 | 0.5714 | 4 | 7 | 44,500 | 9,000 |
2008-06-01 | 1.0 | 7 | 7 | 25,450 | 9,000 |
2008-03-01 | 0.2376 | 24 | 101 | 516,823 | 402,307 |
2007-12-01 | 0.6667 | 2 | 3 | 38,500 | 514,052 |
2007-09-01 | 1.0 | 1 | 1 | 130,000 | 0.00 |
2007-06-01 | 0.5672 | 38 | 67 | 27,125,367 | 47,226,066 |
Insulet Notable Stakeholders
An Insulet stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Insulet often face trade-offs trying to please all of them. Insulet's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Insulet's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
James Hollingshead | CEO President | Profile | |
Eric Benjamin | Senior Vice President R&D, New Product Development and Commercialization | Profile | |
John Kapples | Senior Vice President General Counsel, Secretary | Profile | |
Wayde McMillan | CFO, Executive Vice President | Profile | |
Charles Alpuche | Senior Vice President Global Manufacturing and Operations | Profile | |
Michael Spears | Senior Vice President Quality, Regulatory, and Clinical Affairs | Profile | |
Ana Chadwick | CFO VP | Profile | |
Mark Field | Senior CTO | Profile | |
Philip Hildale | Senior Care | Profile | |
Prem Singh | Senior Operations | Profile | |
Laetitia Cousin | Quality Affairs | Profile | |
John JD | Senior Counsel | Profile | |
Angela Wiczek | Senior Communications | Profile | |
Lauren Budden | Chief VP | Profile | |
Bret Christensen | Chief Commercial Officer | Profile | |
Deborah CPA | Vice Relations | Profile | |
Shacey Petrovic | Chief Commercial Officer | Profile |
About Insulet Management Performance
The success or failure of an entity such as Insulet often depends on how effective the management is. Insulet management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Insulet management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Insulet management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.08 | 0.09 | |
Return On Capital Employed | 0.10 | 0.11 | |
Return On Assets | 0.08 | 0.08 | |
Return On Equity | 0.28 | 0.30 |
Please note, the presentation of Insulet's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Insulet's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Insulet's management manipulating its earnings.
Insulet Workforce Analysis
Traditionally, organizations such as Insulet use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Insulet within its industry.Insulet Manpower Efficiency
Return on Insulet Manpower
Revenue Per Employee | 565.7K | |
Revenue Per Executive | 99.8M | |
Net Income Per Employee | 68.8K | |
Net Income Per Executive | 12.1M | |
Working Capital Per Employee | 377.2K | |
Working Capital Per Executive | 66.6M |
Complementary Tools for Insulet Stock analysis
When running Insulet's price analysis, check to measure Insulet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insulet is operating at the current time. Most of Insulet's value examination focuses on studying past and present price action to predict the probability of Insulet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insulet's price. Additionally, you may evaluate how the addition of Insulet to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |